Methods and marker combinations for screening for predisposition to lung cancer

Patent metadata

Field	Value
Publication number	US-9347945-B2
Application number	US-77172707-A
Country	US
Kind code	B2
Filing date	Jun 29, 2007
Priority date	Dec 22, 2005
Publication date	May 24, 2016
Grant date	May 24, 2016

Abstract

The present invention relates to rapid, sensitive methods for determining whether a subject is at risk of developing lung cancer or has lung cancer based on certain combinations or biomarkers or biomarkers and biometric parameters.

First claim

What is claimed is:

1. A method of aiding in a diagnosis of a subject suspected of lung cancer, the method comprising the steps of:
(a) quantifying in a test sample obtained from a subject the amount of biomarkers: anti-p53, anti-NY-ESO-1, proGRP, CEA, cytokeratin 19, CA125, and human amyloid protein A;
(b) comparing the amount of each quantified biomarker to a number of predetermined cutoffs for said biomarker and assigning one of a number of predetermined weighted scores for each biomarker based on said comparison, wherein the assigned weighted score for each biomarker is calculated based on a specificity of the predetermined cutoff nearest to and less than the quantified amount of said biomarker, wherein the specificities of the number of predetermined cutoffs are 0.9, 0.75 and 0.5, and wherein the weighted score is zero if the amount of the biomarker is less than the lowest predetermined cutoff for the biomarker;
(c) combining the assigned weighted score for each biomarker quantified in step a to obtain a total score for said subject;
(d) comparing the total score determined in step c with a predetermined total score; and
(e) determining whether said subject has lung cancer based on the comparison of the total score in step d;
wherein the Distance from Ideal (DFI) of the biomarkers relative to lung cancer is less than about 0.4.

2. The method of claim 1 , further comprising quantifying in the test sample the amount of at least one biomarker selected from the group consisting of: anti-TMP21, anti-HDJ1, anti-NPC1L1C-domain, anti-TMOD1, anti-CAMK1, anti-RGS1, anti-PACSIN1, anti-RCV1, anti-MAPKAPK3, and anti-Cyclin E2.

3. The method of claim 1 , further comprising quantifying in the test sample the amount of at least one biomarker selected from the group consisting of: cytokeratin 8, cytokeratin 18, CA19-9, CA15-3, SCC, alpha-1-anti-trypsin, apolipoprotein CIII and thymosin β4.

4. A method of aiding in a diagnosis of a subject suspected of lung cancer, the method comprising the steps of:
(a) obtaining a value for at least one biometric parameter of a subject;
(b) comparing the value of the at least one biometric parameter against a predetermined cutoff for each said biometric parameter and assigning a score for each biometric parameter based on said comparison;
(c) quantifying in a test sample obtained from a subject the amount of biomarkers: anti-p53, anti-NY-ESO-1, proGRP, CEA, cytokeratin 19, CA125, and human amyloid protein A;
(d) comparing the amount of each quantified biomarker to a number of predetermined cutoffs for said biomarker and assigning one of a number of predetermined weighted scores for each biomarker based on said comparison, wherein the assigned weighted score for each biomarker is calculated based on a specificity of the predetermined cutoff nearest to and less than the quantified amount of said biomarker, wherein the specificities of the number of predetermined cutoffs are 0.9, 0.75 and 0.5, and wherein the weighted score is zero if the amount of the biomarker is less than the lowest predetermined cutoff for the biomarker;
(e) combining the assigned weighted score for each biomarker quantified in step c and the assigned score for each biometric parameter in step b to obtain a total score for said subject;
(f) comparing the total score determined in step e with a predetermined total score; and
(g) determining whether said subject has lung cancer based on the comparison of the total score in step f,
wherein the Distance from Ideal (DFI) of the biomarkers relative to lung cancer is less than about 0.4.

5. The method of claim 4 , further comprising quantifying in the test sample the amount of at least one biomarker selected from the group consisting of: anti-TMP21, anti-HDJ1, anti-NPC1L1C-domain, anti-TMOD1, anti-CAMK1, anti-RGS1, anti-PACSIN1, anti-RCV1, anti-MAPKAPK3, and anti-Cyclin E2.

6. The method of claim 4 , further comprising quantifying in the test sample the amount of at least one biomarker selected from the group consisting of: cytokeratin 8, cytokeratin 18, CA15-3, SCC, CA19-9, alpha-1-anti-trypsin, apolipoprotein CIII and thymosin β4.

7. The method of claim 4 , wherein the biometric parameter is selected from the group consisting of: the subject's smoking history, age, carcinogen exposure, and gender.

8. The method of claim 7 , wherein the biometric parameter is pack-years of smoking.

9. The method of claim 4 , wherein step b comprises comparing the value of each biometric parameter against a number of predetermined cutoffs for said biometric parameter and assigning one of a number of possible scores for each said biometric parameter based on said comparison.

10. The method of claim 4 , wherein the biometric parameter is pack-years of smoking.

11. The method of claim 1 , wherein the method comprises quantifying the amount of seven or more biomarkers.

12. The method of claim 4 , wherein the method comprises quantifying the amount of seven or more biomarkers.

Assignees

• Colpitts Tracey
• Russell Eric L
• Frost Stephen
• Ramirez Javier
• Singh Bhawani
• Russell John C
• Abbott Molecular Inc

Inventors

• Colpitts Tracey
• Russell Eric L
• Frost Stephen
• Ramirez Javier
• Singh Bhawani
• Russell John C

Classifications

• G01N33/5752 Primary

  of the lungs · CPC title

• G01N2333/91205

  Phosphotransferases in general · CPC title

• G01N2333/4748

  p53 · CPC title

• G01N2333/4739

  Cyclin; Prad 1 · CPC title

• G01N2333/47

  Assays involving proteins of known structure or function as defined in the subgroups · CPC title